{
  "id": 1951180,
  "title": "Engineering a pH-sensitive humanized infliximab with improved potency and developability using STEM™",
  "url": "https://urgent.news/2026/08/19/engineering-a-ph-sensitive-humanized-infliximab-with-improved-potency",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-19T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.18.745573v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Background: Tumor necrosis factor- inhibitors such as infliximab and adalimumab have transformed autoimmune disease treatment; however, infliximab is a mouse-human chimeric antibody that remains immunogenic, is associated with self-association/aggregation liability, and requires prolonged intravenous administration. We humanized infliximab and engineered infliximab-derived candidates with…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}